Loading...
Publication
Secukinumab on Refractory Lupus Nephritis
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 151.3 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Lupus nephritis (LN) is the most frequent severe organ manifestation of systemic lupus erythematosus (SLE). About 30% of patients are refractory to treatment. The authors report a case of treatment of LN with interleukin-17-targeted therapy, demonstrating its possible benefit, after reports of T helper 17 cell involvement in SLE pathogenesis. We present the case of a childbearing age woman with SLE, who developed refractory LN despite all the indicated therapeutic options. During follow up, infection with human papillomavirus was detected, a possible trigger, and the following management was based on this discovery. We currently know that cytokines play a major role in tissue damage and interleukin-17 (IL-17) seems to be a fundamental key in SLE and LN, having shown its expression in renal glomeruli and urinary sediment. Thus, it was decided to start treatment with an anti-IL-17A antibody, secukinumab. After starting secukinumab, clinical and biological features improved and complete renal response was achieved.
Description
Keywords
cytokines il-17 inhibitor therapy immunosuppressive therapy lupus nephritis proteinuria secukinumab systemic lupus erythematosus th17 cells
Citation
Costa R, Antunes P, Salvador P, Oliveira P, Marinho A. Secukinumab on Refractory Lupus Nephritis. Cureus. 2021;13(8):e17198. Published 2021 Aug 15. doi:10.7759/cureus.17198
Publisher
Cureus, Inc.